The effect of Helicobacter pylori infection and eradication in patients with gastro-oesophageal reflux disease: A parallel-group, double-blind, placebo-controlled multicentre study

United European Gastroenterology Journal

Volumn 1, Issue 4, 2013, Pages 226-235

  Schwizer, Werner ^a,b   Menne, Dieter ^c   Schütze, Kurt ^d   Vieth, Michael ^e   Goergens, Reiner ^e   Malfertheiner, Peter ^f   Leodolter, Andreas ^g   Fried, Michael ^a,b   Fox, Mark R ^a,b,h  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c Menne Biomed   (Germany)

^d HANUSCH HOSPITAL   (Austria)

^e INSTITUTE OF PATHOLOGY   (Germany)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Esomeprazole; Gastritis; Gastro oesophageal reflux disease; H. pylori eradication therapy; Helicobacter pylori; Oesophagitis; Symptomatic relapse

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; BIOPSY; CONTROLLED STUDY; DISEASE ERADICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ENDOSCOPY; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; VIRAL CLEARANCE;

EID: 85006217685     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640613484020     Document Type: Article

References (42)

1. Fox M and Forgacs I. Gastro-oesophageal reflux disease. BMJ 2006; 332: 88-93.
2. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831.
3. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90: 1401-1406.
4. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-965.
5. Graham KS and Graham DY. Helicobacter pylori, gastroesophageal reflux disease, Barrett's esophagus, and adenocarcinoma of the distal esophagus. In: Contemporary diagnosis and management of Helicobacter pylori-associated gastrointestinal diseases, 2nd ed. Newtown: Pennsylvania, 2002, pp. 128-147.
6. Newton M, Bryan R, Burnham WR, et al. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997; 40: 9-13.
7. Hackelsberger A, Schultze V, Gunther T, et al. The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: a case-control study. Eur J Gastroenterol Hepatol 1998; 10: 465-468.
8. Csendes A, Smok G, Cerda G, et al. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus 1997; 10: 38-42.
9. Raghunath A, Hungin AP, Wooff D, et al. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003; 326: 737.
10. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcin- oma. Cancer Res 1998; 58: 588-590.
11. Whiteman DC, Parmar P, Fahey P, et al. Association of Helicobacter pylori infection with reduced risk for esophageal cancer is independent of environmental and genetic modifiers. Gastroenterology 2010; 139: 73-83. quiz e11-e12.
12. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-732.
13. Holtmann G, Cain C and Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-16.
14. Labenz J, Blum AL, Bayerdorffer E, et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-1447.
15. Fallone CA, Barkun AN, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroeso-phageal reflux disease? Am J Gastroenterol 2000; 95: 914-920.
16. Vakil N, Hahn B and McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 45-51.
17. McColl KE, Dickson A, El-Nujumi A, et al. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 101-105.
18. Malfertheiner P, Dent J, Zeijlon L, et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease results from a randomized trial programme. Aliment Pharmacol Ther 2002; 16: 1431-1442.
19. Moayyedi P, Bardhan C, Young L, et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-1126.
20. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001; 357: 1738-1742.
21. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53: 12-20.
22. Wu JC, Chan FK, Wong SK, et al. Effect ofHelicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment Pharmacol Ther 2002; 16: 545-552.
23. Pilotto A, Perri F, Leandro G, et al. Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study. Gerontology 2006; 52: 99-106.
24. Graham DY. Helicobacter pylori infection in the patho-genesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 1997; 113: 1983-1991.
25. Menne D. Eraflux score. Tuebingen: Menne Biomed, 2010.
26. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-180.
27. Leodolter A, Dominguez-Munoz JE, von Arnim U, et al. Validity of a modified 13C -urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999; 94: 2100-2104.
28. Tulassay Z, Kryszewski A, Dite P, et al. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol 2001; 13: 1457-1465.
29. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-1258.
30. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181.
31. R Development Core Team. R: a language and environment for statistical computing. 2.0.1 ed. Vienna, Austria: R Foundation for Statistical Computing, 2011.
32. Cox D. Regression models and life tables. Journal of the Royal Statistical Society 1972; 34: 187-220.
33. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006; 101: 2457-2462.
34. National Institute of Health and Clinical Excellance. Dyspepsia: managing dyspepsia in adults in primary care. London, Newcastle on Tyne: NICE, North of England Dyspepsia Guideline Development Group, 2004.
35. Dorn SD, Hernandez L, Minaya MT, et al. Psychosocial factors are more important than disease activity in determining gastrointestinal symptoms and health status in adults at a celiac disease referral center. Dig Dis Sci 2010; 55: 3154-3163.
36. Gillen D, Wirz AA, Ardill JE, et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 239-247.
37. Sandgren JE, McPhee MS and Greenberger NJ. Narcotic bowel syndrome treated with clonidine. Resolution of abdominal pain and intestinal pseudo-obstruction. Ann Intern Med 1984; 101: 331-334.
38. Gutierrez O, Melo M, Segura AM, et al. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32: 664-668.
39. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999; 94: 3468-3472.
40. Saha A, Backert S, Hammond CE, et al. Helicobacter pylori CagL activates ADAM17 to induce repression of the gastric H, K-ATPase alpha subunit. Gastroenterology 2010; 139: 239-248.
41. Saha A, Hammond CE, Beeson C, et al. Helicobacter pylori represses proton pump expression and inhibits acid secretion in human gastric mucosa. Gut 2010; 59: 874-881.
42. Chourasia D, Achyut BR, Tripathi S, et al. Genotypic and functional roles of IL-1B and IL-1RN on the risk of gastroesophageal reflux disease: the presence of IL-1B-511*T/IL-1RN*1 (T1) haplotype may protect against the disease. Am J Gastroenterol 2009; 104: 2704-2713.